Guggenheim downgraded Travere Therapeutics to Neutral from Buy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Travere Therapeutics submits sNDA for FILSPARI for IgAN
- Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
- Travere Therapeutics to Present at Upcoming Investor Conferences
- Travere’s Sparsentan Nears European Market Breakthrough